Alaunos Therapeutics (TCRT) EBIAT (2016 - 2025)
Historic EBIAT for Alaunos Therapeutics (TCRT) over the last 15 years, with Q3 2025 value amounting to -$1.2 million.
- Alaunos Therapeutics' EBIAT fell 283.94% to -$1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.0 million, marking a year-over-year increase of 6583.48%. This contributed to the annual value of -$4.7 million for FY2024, which is 8668.47% up from last year.
- According to the latest figures from Q3 2025, Alaunos Therapeutics' EBIAT is -$1.2 million, which was down 283.94% from -$1.1 million recorded in Q2 2025.
- Alaunos Therapeutics' 5-year EBIAT high stood at -$742000.0 for Q4 2024, and its period low was -$22.7 million during Q3 2021.
- For the 5-year period, Alaunos Therapeutics' EBIAT averaged around -$7.7 million, with its median value being -$8.6 million (2023).
- Its EBIAT has fluctuated over the past 5 years, first plummeted by 2190.79% in 2021, then surged by 9053.93% in 2024.
- Quarter analysis of 5 years shows Alaunos Therapeutics' EBIAT stood at -$11.8 million in 2021, then increased by 22.34% to -$9.2 million in 2022, then grew by 14.37% to -$7.8 million in 2023, then skyrocketed by 90.54% to -$742000.0 in 2024, then tumbled by 56.2% to -$1.2 million in 2025.
- Its EBIAT was -$1.2 million in Q3 2025, compared to -$1.1 million in Q2 2025 and -$1.1 million in Q1 2025.